Tuesday, Intra-Cellular Therapies Inc ( ITCI ) released topline results from Study 502 evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD).  The company expects to submit a supplemental FDA application in the second half of 2024. Lumateperone 42 mg, given once daily as adjunctive therapy to antidepressants, met the primary...

10:37 AM EDT, 06/18/2024 (MT Newswires) -- Fitch Ratings has affirmed the long-term issuer default rating and short-term issuer default rating on Canadian Imperial Bank Of Commerce's ( CM ) , Bank of Nova Scotia's ( BNS ) , and Bank of Montreal's ( NRGD ) at AA- and F1+, respectively. Also, Fitch affirmed the ratings of the bank's subsidiaries...

LONDON - Commodity trader Trafigura sent a letter last week to current and former employees proposing share clawbacks for breaches of confidentiality and its code of conduct, two sources with knowledge of the matter told Reuters. Clawbacks are typically used by financial firms which require money already paid out to employees to be returned in the event of misconduct or...

10:37 AM EDT, 06/18/2024 (MT Newswires) -- JAKKS Pacific's ( JAKK ) Disguise business unit said Tuesday that it signed a multi-year licensing agreement with Aniplex of America covering the Demon Slayer: Kimetsu no Yaiba animated series in North America, Australia, New Zealand, LATAM, Ireland, and the UK. The deal allows Disguise to design, develop, and manufacture costume accessories based...